Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"US WorldMeds","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","amount":"$530.0 million ","upfrontCash":"$300.0 million","newsHeadline":"Supernus to Acquire CNS Portfolio from US WorldMeds","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Adamis Pharmaceuticals","pharmaFlowCategory":"D","amount":"$26.0 million","upfrontCash":"Undisclosed","newsHeadline":"Adamis Pharmaceuticals Announces Distribution and Commercialization Agreement for SYMJEPI and ZIMHI with US WorldMeds","therapeuticArea":"Immunology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Immunology","graph2":"Approved"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Supernus Completes Acquisition of CNS Portfolio from US WorldMeds","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"US WorldMeds","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"US WorldMeds Advances Partnership With FEMA And Healthcare Ready During Coronavirus Pandemic","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Norgine","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Norgine Enter Agreement to Commercialise DFMO in Independent States","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Panbela Therapeutics","pharmaFlowCategory":"D","amount":"$9.5 million","upfrontCash":"Undisclosed","newsHeadline":"Panbela Therapeutics to Receive a Total Up to $9.5 Million for Divestiture of Assets within Eflornithine (DFMO) Pediatric Neuroblastoma Program to US WorldMeds","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"July 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"US WorldMeds Announces FDA Approval of IWILFIN\u2122 (eflornithine) to Strengthen Fight Against Aggressive Childhood Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Approves Eflornithine for Adult and Pediatric Patients with High-Risk Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"US WorldMeds","sponsor":"Panbela Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Panbela Therapeutics Announces US WorldMeds NDA Approval for Eflornithine (DFMO) in Pediatric Neuroblastoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by US WorldMeds

    Menu

    US WorldMeds

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              US WorldMeds

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Panbela Therapeutics Announces US WorldMeds NDA Approval for Eflornithine (DFMO) in Pediatric Neuroblastoma

              Details:

              CPP-1X-T (eflornithine) is a single agent tablet or high dose powder sachet for several indications including prevention of gastric cancer, treatment of neuroblastoma and recent onset type 1 diabetes. It is approved by USFDA for the treatment of Pediatric Neuroblastoma.

              Lead Product(s): Eflornithine

              Therapeutic Area: Oncology Product Name: CPP-1X-T

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Panbela Therapeutics

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 18, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              US WorldMeds

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              US WorldMeds Announces FDA Approval of IWILFIN™ (eflornithine) to Strengthen Fight Against Aggressive Childhood Cancer

              Details:

              Iwilfin (eflornithine) is an ornithine decarboxylase inhibitor used to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB).

              Lead Product(s): Eflornithine

              Therapeutic Area: Oncology Product Name: Iwilfin

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 14, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              US WorldMeds

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              FDA Approves Eflornithine for Adult and Pediatric Patients with High-Risk Neuroblastoma

              Details:

              Iwilfin (eflornithine) is an ornithine decarboxylase inhibitor used to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB).

              Lead Product(s): Eflornithine

              Therapeutic Area: Oncology Product Name: Iwilfin

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 14, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              US WorldMeds

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Panbela Therapeutics to Receive a Total Up to $9.5 Million for Divestiture of Assets within Eflornithine (DFMO) Pediatric Neuroblastoma Program to US WorldMeds

              Details:

              Panbela has divested certain assets in its eflornithine pediatric neuroblastoma program including, CPP-1X (eflornithine), being developed for several indications including prevention of gastric cancer, treatment of neuroblastoma and recent onset Type 1 diabetes.

              Lead Product(s): Eflornithine

              Therapeutic Area: Oncology Product Name: CPP-1X

              Highest Development Status: Phase II Product Type: Small molecule

              Recipient: Panbela Therapeutics

              Deal Size: $9.5 million Upfront Cash: Undisclosed

              Deal Type: Divestment July 19, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              US WorldMeds

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Norgine Enter Agreement to Commercialise DFMO in Independent States

              Details:

              DFMO is a repurposed molecule investigated for use as an extended maintenance treatment for high-risk neuroblastoma (HRNB) in paediatric patients with no active disease (NAD) / no evidence of disease (NED) after first line multiagent, multimodality therapy.

              Lead Product(s): Eflornithine

              Therapeutic Area: Oncology Product Name: DFMO

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Norgine

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement July 23, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              US WorldMeds

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              US WorldMeds Advances Partnership With FEMA And Healthcare Ready During Coronavirus Pandemic

              Details:

              US WorldMeds, in conjunction with FEMA and their partnership with Healthcare Ready, is making a donation of LUCEMYRA valued at approximately $100,000 to NorthLakes Community Clinic, a federally qualified health center located in northern Wisconsin.

              Lead Product(s): Lofexidine

              Therapeutic Area: Psychiatry/Psychology Product Name: Lucemyra

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Federal Emergency Management Agency

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Partnership October 06, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              US WorldMeds

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Supernus Completes Acquisition of CNS Portfolio from US WorldMeds

              Details:

              This acquisition significantly expands Supernus' business in CNS and increases and diversifies its revenue and earnings streams, while continuing to maintain a strong balance sheet.

              Lead Product(s): Apomorphine Hydrochloride

              Therapeutic Area: Neurology Product Name: Apokyn

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Supernus Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Acquisition June 09, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              US WorldMeds

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Adamis Pharmaceuticals Announces Distribution and Commercialization Agreement for SYMJEPI and ZIMHI with US WorldMeds

              Details:

              US WorldMeds obtained U.S. rights to commercialize and distribute the SYMJEPI products, upon the termination of Sandoz’ commercial rights, and ZIMHI.

              Lead Product(s): Epinephrine

              Therapeutic Area: Immunology Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Small molecule

              Recipient: Adamis Pharmaceuticals

              Deal Size: $26.0 million Upfront Cash: Undisclosed

              Deal Type: Agreement May 11, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              US WorldMeds

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Supernus to Acquire CNS Portfolio from US WorldMeds

              Details:

              Acquisition adds three products developed and sold in the U.S. market with a late-stage development candidate in the Supernus pipeline: APOKYN ®, MYOBLOC ® XADAGO ® and Apomorphine Infusion Pump.

              Lead Product(s): Apomorphine Hydrochloride

              Therapeutic Area: Neurology Product Name: Apokyn

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Supernus Pharmaceuticals

              Deal Size: $530.0 million Upfront Cash: $300.0 million

              Deal Type: Acquisition April 28, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY